Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00323869 · ClinicalTrials.gov registry record · Phase 2
Phase II Bevacizumab, Gemcitabine and Carboplatin in Newly Diagnosed Non-Small Cell Lung Cancer
A Phase 2 study of Lung Cancer and Non-small Cell Lung Cancer (NSCLC), sponsored by Stanford University.
- Completed
- Registry status
- Phase 2
- Development phase
- 48
- Enrollment target
- 3
- Study locations
NCT00323869 is a Phase 2 study of Lung Cancer and Non-small Cell Lung Cancer (NSCLC) that has completed, run by Stanford University. The registered enrollment target is 48 participants, below the 936-participant average among 409 other Lung Cancer trials with a reported enrollment target (95% lower). The trial reports 3 study locations across 1 state.
The verdict
NCT00323869, a Phase 2 study of Lung Cancer and Non-small Cell Lung Cancer (NSCLC), has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 48 participants
- Enrollment target
- 3
- Study locations
Study Summary
A multi-center study of bevacizumab in combination with gemcitabine and carboplatin as treatment for newly-diagnosed advanced non-small cell lung cancer (NSCLC).
Conditions Studied
Interventions
- DRUG Bevacizumab
- DRUG Carboplatin
- DRUG Gemcitabine
Study Locations (3)
California
- VA Palo Alto Healthcare System - Palo Alto
- Santa Clara Valley Medical Center - San Jose
- Stanford University School of Medicine - Stanford
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2006-06 |
| Est. Completion | 2013-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00323869
The ClinicalTrials.gov registry entry for NCT00323869 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 936-participant average among 409 other Lung Cancer trials with a reported enrollment target (95% lower). The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Lung Cancer appearing as the primary indexed condition, and to 3 interventions - of which Bevacizumab is the first listed.
NCT00323869 reports 3 study locations spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT00323869 about?
NCT00323869 is a clinical study titled "Phase II Bevacizumab, Gemcitabine and Carboplatin in Newly Diagnosed Non-Small Cell Lung Cancer". A multi-center study of bevacizumab in combination with gemcitabine and carboplatin as treatment for newly-diagnosed advanced non-small cell lung cancer (NSCLC).
What is the current status of trial NCT00323869?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 48 participants. The study started on 2006-06. Estimated completion is 2013-10.
What conditions does trial NCT00323869 study?
This clinical trial studies the following conditions: Lung Cancer, Non-small Cell Lung Cancer (NSCLC).
What interventions are being tested in trial NCT00323869?
The interventions under investigation include: Bevacizumab (DRUG), Carboplatin (DRUG), Gemcitabine (DRUG).
Who is sponsoring clinical trial NCT00323869?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00323869 being conducted?
This trial has 3 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Novel Treatment Combinations in Patients With Lung Cancer
RECRUITING · Phase 2
-
Feasibility Study to Treat Lung Cancer With the Permanently Implantable LDR CivaSheet®
RECRUITING · Phase 2
-
ATATcH Alternating Treatment Plans for Advanced Cancer
RECRUITING · Phase 2
-
A Phase II Study of Neoadjuvant Sotorasib in Combination With Cisplatin or Carboplatin and Pemetrexed for Surgically Resectable Stage IIA-IIIB Non-Squamous Non-Small Cell Lung Cancer With a KRAS p.G12C Mutation
RECRUITING · Phase 2
-
Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial
RECRUITING · Phase 2
-
Evaluation of PET Probe [68Ga]CBP8 in the Detection of Radiation Induced Tissue Injury
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.